These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 31140829

  • 1. Downregulation of LINC00515 in high-grade serous ovarian cancer and its relationship with platinum resistance.
    Ni MW, Zhou J, Zhang YL, Zhou GM, Zhang SJ, Feng JG, Xu Q, Zhou Y, Mou HZ, Zheng ZG.
    Biomark Med; 2019 May; 13(7):535-543. PubMed ID: 31140829
    [Abstract] [Full Text] [Related]

  • 2. Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer.
    Fang L, Wang H, Li P.
    Invest New Drugs; 2018 Apr; 36(2):187-194. PubMed ID: 29082457
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Unveiling the epigenomic mechanisms of acquired platinum-resistance in high-grade serous ovarian cancer.
    Silva R, Glennon K, Metoudi M, Moran B, Salta S, Slattery K, Treacy A, Martin T, Shaw J, Doran P, Lynch L, Jeronimo C, Perry AS, Brennan DJ.
    Int J Cancer; 2023 Jul 01; 153(1):120-132. PubMed ID: 36883413
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma.
    Cohen S, Mosig R, Moshier E, Pereira E, Rahaman J, Prasad-Hayes M, Halpert R, Billaud JN, Dottino P, Martignetti JA.
    Gynecol Oncol; 2014 Sep 01; 134(3):591-8. PubMed ID: 24995581
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Targeting estrogen metabolism in high-grade serous ovarian cancer shows promise to overcome platinum resistance.
    Marolt N, Pavlič R, Kreft T, Gjogorska M, Rižner TL.
    Biomed Pharmacother; 2024 Aug 01; 177():117069. PubMed ID: 38968802
    [Abstract] [Full Text] [Related]

  • 13. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA, Todeschini P, Siegel ER, Calza S, Cappella P, Ardighieri L, Cadei M, Bugatti M, Romani C, Bandiera E, Zanotti L, Tassone L, Guarino D, Santonocito C, Capoluongo ED, Beltrame L, Erba E, Marchini S, D'Incalci M, Donzelli C, Santin AD, Pecorelli S, Sartori E, Bignotti E, Odicino F, Ravaggi A.
    J Exp Clin Cancer Res; 2017 May 08; 36(1):63. PubMed ID: 28482906
    [Abstract] [Full Text] [Related]

  • 14. Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients.
    Buttarelli M, Ciucci A, Palluzzi F, Raspaglio G, Marchetti C, Perrone E, Minucci A, Giacò L, Fagotti A, Scambia G, Gallo D.
    J Exp Clin Cancer Res; 2022 Feb 04; 41(1):50. PubMed ID: 35120576
    [Abstract] [Full Text] [Related]

  • 15. Upregulation of the Long Noncoding RNA CASC10 Promotes Cisplatin Resistance in High-Grade Serous Ovarian Cancer.
    Noriega-Rivera R, Rivera-Serrano M, Rabelo-Fernandez RJ, Pérez-Santiago J, Valiyeva F, Vivas-Mejía PE.
    Int J Mol Sci; 2022 Jul 13; 23(14):. PubMed ID: 35887085
    [Abstract] [Full Text] [Related]

  • 16. Cox-LASSO Analysis Reveals a Ten-lncRNA Signature to Predict Outcomes in Patients with High-Grade Serous Ovarian Cancer.
    Xu L, Wu Y, Che X, Zhao J, Wang F, Wang P, Qu X, Liu Y, Li Z.
    DNA Cell Biol; 2019 Dec 13; 38(12):1519-1528. PubMed ID: 31657627
    [Abstract] [Full Text] [Related]

  • 17. Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment.
    van Zyl B, Tang D, Bowden NA.
    Endocr Relat Cancer; 2018 May 13; 25(5):R303-R318. PubMed ID: 29487129
    [Abstract] [Full Text] [Related]

  • 18. Knockdown of Linc00515 Inhibits Multiple Myeloma Autophagy and Chemoresistance by Upregulating miR-140-5p and Downregulating ATG14.
    Lu D, Yang C, Zhang Z, Cong Y, Xiao M.
    Cell Physiol Biochem; 2018 May 13; 48(6):2517-2527. PubMed ID: 30121664
    [Abstract] [Full Text] [Related]

  • 19. The clinical significance and biological function of lncRNA SOCAR in serous ovarian carcinoma.
    Guo Q, Wang L, Zhu L, Lu X, Song Y, Sun J, Wu Z, Shi J, Wang Z, Zhou X.
    Gene; 2019 Sep 10; 713():143969. PubMed ID: 31299360
    [Abstract] [Full Text] [Related]

  • 20. Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.
    Lambrechts S, Smeets D, Moisse M, Braicu EI, Vanderstichele A, Zhao H, Van Nieuwenhuysen E, Berns E, Sehouli J, Zeillinger R, Darb-Esfahani S, Cacsire Castillo-Tong D, Lambrechts D, Vergote I.
    Eur J Cancer; 2016 Jan 10; 53():51-64. PubMed ID: 26693899
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.